Display options
Cite
Ryan K, Anderson M, Gyurova I, et al. High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infect Dis. 2017;4(4):ofx195doi: 10.1093/ofid/ofx195.
Ryan, K., Anderson, M., Gyurova, I., Ambroggio, L., Moyo, S., Sebunya, T., Makhema, J., Marlink, R., Essex, M., Musonda, R., Gaseitsiwe, S., & Blackard, J. T. (2017). High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open forum infectious diseases, 4(4), ofx195. https://doi.org/10.1093/ofid/ofx195
Ryan, Kathleen, et al. "High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana." Open forum infectious diseases vol. 4,4 (2017): ofx195. doi: https://doi.org/10.1093/ofid/ofx195
Ryan K, Anderson M, Gyurova I, Ambroggio L, Moyo S, Sebunya T, Makhema J, Marlink R, Essex M, Musonda R, Gaseitsiwe S, Blackard JT. High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana. Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195. doi: 10.1093/ofid/ofx195. eCollection 2017. PMID: 29062862; PMCID: PMC5641381.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2017 Sep 13;4(4):ofx195. doi: 10.1093/ofid/ofx195. eCollection 2017.

High Rates of Occult Hepatitis B Virus Infection in HIV-Positive Individuals Initiating Antiretroviral Therapy in Botswana.

Open forum infectious diseases

Kathleen Ryan, Motswedi Anderson, Ivayla Gyurova, Lilliam Ambroggio, Sikhulile Moyo, Teresa Sebunya, Joseph Makhema, Richard Marlink, Max Essex, Rosemary Musonda, Simani Gaseitsiwe, Jason T Blackard

Affiliations

  1. University of Cincinnati College of Medicine, Cincinnati, Ohio.
  2. Botswana Harvard AIDS Institute Partnership, Gaborone, Botswana.
  3. Department of Biological Sciences, University of Botswana, Gaborone, Botswana.
  4. Department of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, Massachusetts.

PMID: 29062862 PMCID: PMC5641381 DOI: 10.1093/ofid/ofx195

Abstract

BACKGROUND: Hepatitis B surface antigen (HBsAg)-negative but hepatitis B virus (HBV) DNA-positive infection-known as

METHODS: Two hundred seventy-two adults enrolled in an HIV treatment study of tenofovir/emtricitabine as the nucleoside backbone who were previously determined to be HBsAg negative were tested for HBV DNA at baseline and 1 year after initiation of highly active antiretroviral therapy (HAART).

RESULTS: HBV DNA was detected in 72 of 272 (26.5%). Six individuals (8.3%) had HBV DNA levels greater than 200 IU/mL, and the highest viral load was 3280 IU/mL. Of 65 participants with OBI evaluated at 12 months after initiating HAART, only 1 (1.5%) had detectable HBV DNA.

CONCLUSIONS: Occult HBV infection is quite common in HIV-infected patients in Botswana, although its impact on the course of HIV disease progression is unknown. The suppression of occult HBV DNA levels by tenofovir/emtricitabine suggests an effective therapeutic option, although the long-term suppressive abilities remain unstudied.

Keywords: Africa; Botswana; HBV; HIV; HIV/HBV; hepatitis B virus; occult; tenofovir

References

  1. PLoS One. 2012;7(10):e45750 - PubMed
  2. Liver Int. 2015 Mar;35(3):897-904 - PubMed
  3. Clin Infect Dis. 2006 Dec 15;43(12):1612-5 - PubMed
  4. J Med Virol. 2009 Mar;81(3):406-12 - PubMed
  5. HIV Med. 2014 Mar;15(3):189-92 - PubMed
  6. Hepat Mon. 2016 Feb 20;16(2):e34758 - PubMed
  7. Am J Trop Med Hyg. 2011 Aug;85(2):390-4 - PubMed
  8. Lancet. 1988 Dec 3;2(8623):1273-6 - PubMed
  9. Clin Microbiol Rev. 2012 Jan;25(1):142-63 - PubMed
  10. PLoS One. 2015 Oct 12;10(10):e0138552 - PubMed
  11. Clin Infect Dis. 2011 Mar 1;52(5):674-80 - PubMed
  12. AIDS. 2013 Jan 2;27(1):139-41 - PubMed
  13. PLoS One. 2016 Apr 06;11(4):e0152757 - PubMed
  14. J Clin Virol. 2006 Jan;35(1):14-20 - PubMed
  15. J Hepatol. 2006 Jan;44(1):39-46 - PubMed
  16. World J Hepatol. 2013 Oct 27;5(10):584-8 - PubMed
  17. N Engl J Med. 1978 Jun 22;298(25):1379-83 - PubMed
  18. Hepatol Res. 2008 Dec;38(12):1194-203 - PubMed
  19. Gastroenterology. 1988 Jan;94(1):151-6 - PubMed
  20. J Med Virol. 2007 Oct;79(10):1464-71 - PubMed
  21. J Trop Med. 2014;2014:796121 - PubMed
  22. PLoS One. 2015 Jul 28;10(7):e0134037 - PubMed
  23. J Int Assoc Provid AIDS Care. 2013 Sep-Oct;12(5):349-53 - PubMed
  24. J Acquir Immune Defic Syndr. 2007 Mar 1;44(3):309-14 - PubMed
  25. BMC Gastroenterol. 2011 Aug 17;11:91 - PubMed
  26. World J Hepatol. 2015 Feb 27;7(2):253-60 - PubMed
  27. Infection. 1987 Nov-Dec;15(6):434-9 - PubMed
  28. Int J STD AIDS. 2016 Oct;27(11):967-72 - PubMed
  29. Int J Gynaecol Obstet. 2007 Mar;96(3):167-70 - PubMed
  30. J Clin Virol. 2015 Feb;63:12-7 - PubMed
  31. Curr HIV Res. 2008 Mar;6(2):173-9 - PubMed
  32. S Afr Med J. 2015 Dec 16;106(1):97-100 - PubMed
  33. PLoS One. 2015 Oct 05;10(10):e0139551 - PubMed
  34. J Med Virol. 2009 Mar;81(3):441-5 - PubMed
  35. Trans R Soc Trop Med Hyg. 1989 Jan-Feb;83(1):110-6 - PubMed
  36. Eur J Clin Invest. 2015 Dec;45(12 ):1243-51 - PubMed
  37. J Viral Hepat. 2014 Mar;21(3):153-62 - PubMed
  38. J Gastroenterol Hepatol. 2009 Apr;24(4):588-98 - PubMed
  39. J Hepatol. 2012 Sep;57(3):515-21 - PubMed
  40. Open Forum Infect Dis. 2016 Aug 16;3(3):ofw140 - PubMed
  41. Infection. 2011 Apr;39(2):121-6 - PubMed
  42. J Hepatol. 2008 Oct;49(4):652-7 - PubMed
  43. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):174-82 - PubMed
  44. J Med Virol. 2015 Mar;87(3):388-400 - PubMed
  45. J Clin Virol. 2005 Dec;34 Suppl 1:S1-3 - PubMed
  46. PLoS One. 2016 Nov 11;11(11):e0166317 - PubMed
  47. BMC Infect Dis. 2010 Mar 07;10:53 - PubMed

Publication Types

Grant support